Similar articles

• The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.

  Cardozo L, Thorpe A, Warner J, Sidhu M. Cardozo L, et al. BJU Int. 2010 Aug;106(4):506-14. doi: 10.1111/j.1464-410X.2009.09160.x. Epub 2010 Feb 3. BJU Int. 2010. PMID: 20132203
• A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.

  Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J. Speakman M, et al. Curr Med Res Opin. 2008 Aug;24(8):2173-9. doi: 10.1185/03007990802234829. Epub 2008 Jun 18. Curr Med Res Opin. 2008. PMID: 18565239 Clinical Trial.
• Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation.

  Pradelli L, Iannazzo S. Pradelli L, et al. J Med Econ. 2009 Mar;12(1):25-35. doi: 10.3111/13696990902767800. J Med Econ. 2009. PMID: 19450062
• Tolterodine for treatment of overactive bladder.

  Kanofsky JA, Nitti VW. Kanofsky JA, et al. Urol Clin North Am. 2006 Nov;33(4):447-53, viii. doi: 10.1016/j.ucl.2006.06.004. Urol Clin North Am. 2006. PMID: 17011380 Review.
• Fesoterodine for the treatment of overactive bladder.

  Tzefos M, Dolder C, Olin JL. Tzefos M, et al. Ann Pharmacother. 2009 Dec;43(12):1992-2000. doi: 10.1345/aph.1M308. Epub 2009 Nov 17. Ann Pharmacother. 2009. PMID: 19920160 Review.